Drug Targets – Products

Range of highly selective anti-idiotypic antibodies now includes six antibodies specific to dupilumab and its biosimilars for bioanalysis and Drug Monitoring.

Accurate kinetics and affinity data is essential for predicting the efficacy of novel therapeutics and for making quick decisions about weak candidates. However, analysis methods that require labelling can cause steric interference and influence data outcomes.

Sygnature Discovery has established an in vivo LPS model of inflammation which can help understand life-limiting neuroinflammatory conditions like Parkinson’s disease, multiple sclerosis, Alzheimer’s disease, and traumatic brain injuries and identify new drug targets.

This application note demonstrates how reliable kinetics and affinity can be obtained from single measurement data, increasing sample throughput and saving sample material.

Designing and performing assays that accurately measure the binding kinetics of biomolecular interactions requires highly technical skills. Hence, such methods can feel out of reach for many scientists.

Label-free biosensors are changing the game—fast, sensitive, and more predictive. Unlike traditional methods, they boost the odds of finding high-value drug candidates with real therapeutic potential.

This compendium serves as a user-friendly reference for assay design on both bio-layer interferometry (BLI) and surface plasmon resonance (SPR) systems.

Evergreen Discovery and Orbit Discovery Ltd have announced that they have entered into a collaboration to identify specific cell targeting peptides and advance the development of novel radiopharmaceuticals.

Cardiff Oncology, Inc. has announced that the first patient was dosed last month with its investigational drug onvansertib in its Phase II ONSEMBLE trial.

Carterra Inc. launched its latest HT-SPR instrument, the LSAXT, at the Society for Laboratory Automation and Screening (SLAS) Conference and Exhibition in San Diego, CA.